Navigation Links
Phase II trial of Bevacizumab (Avastin) in locally advanced cervical cancer 'promising'
Date:1/15/2014

An article published in the January issue of the International Journal of Radiation Oncology, Biology and Physics reports results of the Radiation Therapy Oncology Group (RTOG) phase II clinical trial of Bevacizumab (Avastin) in addition to cisplatin and pelvic radiation for locally advanced cervical cancer. The group reports that the addition of Bevacizumab to the existing standard of care was safe and showed promising overall results. The 2- and 3- year overall survival rates were 89.8 percent and 80.2 percent, respectively.

"Cervical cancer is a huge problem worldwide, but isn't as big a problem in the United States. So in many ways it tends to become a somewhat overlooked and under-studied disease," says Tracey Schefter, MD, investigator at the University of Colorado Cancer Center, director of the Stereotactic Body Radiation Therapy program at the University of Colorado School of Medicine, and the study's lead author.

Risk factors for cervical cancer include infection with the human papilloma virus (HPV). Screening dramatically reduces both the likelihood of developing cervical cancer and the disease's mortality rate. Combined, these two factors mean that 80 percent of the world's approximately 473,000 yearly cases of cervical cancer occur in the developing world. In the United States, cervical cancer rates have dropped 74 percent over the previous 50 years, but is still diagnosed in approximately 10,000 women per year, with 3,500 deaths due to the disease.

The current phase II clinical trial enrolled 49 eligible patients from 28 institutions in the years 2006-2009. The study previously reported that Bevacizumab was safe and well-tolerated in combination with cisplatin and radiation therapy in this population. Now the group reports on the secondary efficacy endpoints at a median follow-up time of 3.8 years.

Specifically the group evaluated the addition of 10mg/kg bevacizumab every two weeks for 3 cycles during chemoradiation. The overall survival and locoregional control results were favorable in comparison to historical controls of chemoradiation without bevacizumab and warrant further study in a phase III trial.

"Parenthetically, when we were designing this trial, one thing we discussed at length was whether to include a maintenance phase of bevacizumab after chemoradiation. Because of perceived issues with patient compliance at the time, we decided not to add to the overall duration of treatment by adding maintenance Bevacizumab. Based on the recent results of GOG 240 which showed an overall survival benefit when Bevacizumab was added to first line chemotherapy for patients with metastatic disease, a trial addressing the benefit of both concurrent and maintenance bevacizumab for locoregionally advanced cervical cancer will likely need to be done," Schefter says.


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert  

Related medicine news :

1. ALS patients differ on treatment choices in later phases of disease
2. Reach2HD, a Phase II study in Huntingtons disease, launched
3. Analysis of KRYSTEXXA phase III data demonstrates improved health-related quality of life and physical function in refractory chronic gout patients
4. Phase III trial of dapivirine ring begins in Africa: New HIV prevention approach for women
5. IDRI and Medicago announce authorization to initiate a Phase 1 clinical trial for an H5N1 vaccine
6. COPD Foundation and BWH announces second phase of groundbreaking COPDGene project
7. JDRF announces winners of first phase of Agnes Varis Glucose-Responsive Insulin Challenge
8. Positive results from Phase 1/2 stem cell trial reported
9. New monoclonal antibody inhibits tumor growth in advanced solid tumors in phase I clinical trial
10. Teva to present new Phase III data for QNASL® Nasal Aerosol at the 2012 ACAAI Meeting
11. Edison Pharmaceuticals announces initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Phase II trial of Bevacizumab (Avastin) in locally advanced cervical cancer 'promising'
(Date:3/29/2017)... ... March 29, 2017 , ... ... documenting and diagramming network and data center assets and audio-video devices has recently ... request new equipment shapes for free and download shapes and stencils from ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... many scientific laboratories. The assembly protocols involve many repetitive steps and often scientists ... automation, which enables the high-throughput needed, and results in a lower error rate ...
(Date:3/29/2017)... NJ (PRWEB) , ... March 29, 2017 , ... ... School of Gastrointestinal Oncology™ (SOGO™), a specialized continuing medical education conference for clinicians ... 29 at Intercontinental Time Square, New York. , The program will be ...
(Date:3/28/2017)... ... March 28, 2017 , ... A recent Bellwether Education ... quality, the field must first improve teacher preparation program design. It then asserts ... and that decades of input- and outcome-based research has failed to improve teacher ...
(Date:3/28/2017)... Georgia (PRWEB) , ... March 28, 2017 , ... ... to its award-winning team. Ruel Williamson brings his extensive knowledge of appraisals, property ... a leader in the real estate valuation industry for more than 40 years. ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017   Royal ... leader in health technology, and PathAI, a company ... collaborating with the aim to develop solutions that ... of cancer and other diseases. The partnership aims ... enabling this form of artificial intelligence to be ...
(Date:3/29/2017)... Stryker announced today that it has been ... partnership with Great Place to Work (GPTW). We ranked ... list highlights the top U.S. companies with 1,000 or ... demonstrating respect, compassion and concern for their employees, their ... the companies on the list, GPTW asked more than ...
(Date:3/29/2017)... SILVER SPRING, Md. , March 29, 2017 On ... Ocrevus (ocrelizumab) to treat adult patients with relapsing forms ... (PPMS). This is the first drug approved by the ... by a health care professional.  "Multiple ... life," said Billy Dunn , M.D., director of ...
Breaking Medicine Technology: